SCHEMBL3428457

SCHEMBL3428457

O=C1N=C(N2CCCNCC2)S/C1=C\c1ccccc1O

nearest known ligand 0.69

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SENP1 Q9P0U3 1/20 0.69
AMY1A P0DUB6 1/20 0.65
NPC1 O15118 4/20 0.58
RAB9A P51151 3/20 0.58
ALDH1A1 P00352 4/20 0.55
HPGD P15428 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.52
GRIN1 Q05586 1/20 0.51
GRIN2B Q13224 1/20 0.51
KMT2A Q03164 5/20 0.49
MEN1 O00255 4/20 0.49
DCTPP1 Q9H773 1/20 0.48
MAPT P10636 5/20 0.47
LMNA P02545 1/20 0.47
GAA P10253 1/20 0.47
HTT P42858 1/20 0.47
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3428461 1.00 SENP1 (0.69) SENP1AMY1ANPC1RAB9AALDH1A1
SCHEMBL4347477 0.95 SENP1 (0.74) SENP1AMY1ANPC1RAB9AALDH1A1
SCHEMBL4347476 0.95 SENP1 (0.74) SENP1AMY1ANPC1RAB9AALDH1A1
SCHEMBL3428082 0.90 SENP1 (0.80) SENP1AMY1ANPC1RAB9AALDH1A1
SCHEMBL3428798 0.90 SENP1 (0.80) SENP1AMY1ANPC1RAB9AALDH1A1
SCHEMBL3428077 0.90 SENP1 (0.80) SENP1AMY1ANPC1RAB9AALDH1A1
SCHEMBL3428804 0.90 SENP1 (0.80) SENP1AMY1ANPC1RAB9AALDH1A1
SCHEMBL13630086 0.90 SENP1 (0.80) SENP1AMY1ANPC1RAB9AALDH1A1
SCHEMBL4352450 0.88 SENP1 (0.78) SENP1AMY1ANPC1RAB9AALDH1A1
SCHEMBL4352447 0.88 SENP1 (0.78) SENP1AMY1ANPC1RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2250167-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS Chlorion Pharma, Inc. (CA) 2010-11-17 EP disclosed
US-20090275538-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS UNIVERSITE LAVAL (CA) 2009-11-05 US disclosed
US-20090275538-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS UNIVERSITE LAVAL (CA) 2009-11-05 US disclosed
US-20090275538-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS UNIVERSITE LAVAL (CA) 2009-11-05 US disclosed
WO-2009097695-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS CHLORION PHARMA, INC. (CA) 2009-08-13 WO disclosed
WO-2009097695-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS CHLORION PHARMA, INC. (CA) 2009-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275538-A1 ARYLMETHYLIDENE HETEROCYCLES AS NOVEL ANALGESICS OPRL1, OPRK1, AHR SENP1 4049/4885AMY1A 3049/4885NPC1 2712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.